SLBST PHARMA INC.
ST PETERSBURG, FLORIDA

Dan Kim is the CEO of SLBST Pharma and serves on its Board of Directors. Before SLBST’s conception in August of 2016, Dan was the CEO and Founder of parent company DHK Pharma Inc. He has nearly three decades of expertise in global pharmaceutical commercialization, specializing in infectious diseases, oncology, and hospital medical devices that range from wound care to aesthetic products. Throughout his career, he worked with senior executives and scientists at Roche, Pfizer, and Novartis, by developing a unique strategic approach to a therapeutic franchise development with over $1B in investments. In addition, he has led scientific and commercial teams in over a dozen due-diligence efforts, from new product acquisition to life-cycle management. Dan earned his BS degree in psychology from Virginia Commonwealth University and an MBA from Saint Joseph’s University in Philadelphia, Pennsylvania. Furthermore, he has completed advanced executive training at the Tuck School of Business at Dartmouth College in addition to the Wharton School of Business at the University of Pennsylvania. Beat Weidmann is SLBST’s Chief Science Officer and is responsible for managing the scientific, research, and technological operations within SLBST. In addition, Beat is in charge of implementing SLBST’s scientific and research priorities so they align with company goals. In addition to building, coaching, and managing multidisciplinary research departments and development teams, Dr. Weidmann has led the discovery and early development of multiple drug candidates. Several of these new chemical entities have progressed to phase I and phase II clinical proof-of-concept trials. Most notably, Dr. Weidmann has successfully initiated and led the buildup of a new R&D initiative in infectious diseases (antibacterials and antivirals) at Novartis. Other responsibilities included business development and licensing, strategic alliances, and external collaborations to support this new business initiative. Yu Chen, PhD, Vice President, Product Development and Alliance Yu Chen is the Vice President of SLBST Pharma and is responsible for fostering and managing R&D collaborations with academic and industry partners, as well as R&D grants from local and federal funding sources. Through these efforts, Yu works with the CEO, CSO and the rest of the team to achieve current scientific and research goals, and to explore future opportunities for the product pipeline. Endometriosis is a gynecological disease that afflicts women of child-bearing age. It is an inflammatory and estrogen-dependent disease that affects 6-10% of women during their reproductive years and up to 50% of women receiving fertility treatments. Globally, approximately 170 million women suffer from this disease with no known cure to date. -hormonal therapy for the treatment of endometriosis based on groundbreaking discoveries made at the University of South Florida (USF). This work established the efficacy of autophagy inhibitors like hydroxychloroquine (HCQ) as a new therapeutic concept for the treatment of this painful and debilitating condition, affecting up to 10% of women during their reproductive years. We welcome your interest, questions, and comments. Please use the form below to submit an email inquiry. We will read and respond to your message as quickly as possible – usually within one business day.